| Literature DB >> 35283334 |
Diana Calderón1, Paúl A Cárdenas1, Belen Prado-Vivar1, Jay P Graham2, Gabriel Trueba3.
Abstract
OBJECTIVES: The gastrointestinal tract constitutes a complex and diverse ecosystem. Escherichia coli is one of the most frequently studied and characterised species in the gut ecosystem; nevertheless, there has been little research to determine their diversity and population dynamics in the intestines of children over time. We analysed the turnover or dominant E. coli isolates in children faecal matter during 1 year.Entities:
Keywords: Antimicrobial resistance; E. coli, longitudinal; Ecuador; Numerically dominant strains; ST131
Mesh:
Substances:
Year: 2022 PMID: 35283334 PMCID: PMC9232985 DOI: 10.1016/j.jgar.2022.03.002
Source DB: PubMed Journal: J Glob Antimicrob Resist ISSN: 2213-7165 Impact factor: 4.349
Fig. 1.Numerically dominant Escherichia coli isolates showing evidence of permanence in children’s intestines for 3 months. The figure showed five isolates obtained from four children during three periods (approximately 3 months apart). The numbers indicate different alleles of the fumC gene. The isolates showing same fumC allele during three periods were subjected to MLST and represented by sequence types (ST).
Fig. 2.Maximum likelihood tree of whole genome sequences of Escherichia coli isolates belonging to ST131. The analysis shows our sequences from Ecuador compared with sequences of E. coli from different sources in North America, Europe, and Oceania.
Prevalence of phenotypical resistance of Escherichia coli numerically dominant isolates obtained from 22 children during SP I, SP II, and SP III
| Antimicrobials | SPIOct.–Dec. 2018 | SPIIJan.–May 2019 | SPIIIJul.–Dec 2019 | ||
|---|---|---|---|---|---|
| Ampicillin (AM) | 64 (58.2 %) | 60 (54.5 %) | 46 (41.8 %) |
|
|
| Chloramphenicol (C) | 5 (4.5 %) | 12 (10.9 %) | 9 (8.2 %) | 3.090 | 0.213 |
| Imipenem (IPM) | 12 (10.9 %) | 1 (0.9 %) | 7 (6.4 %) |
|
|
| Trim-sulfamet (SXT) | 58 (52.7 %) | 58 (52.7 %) | 50 (45.4 %) | 1.552 | 0.460 |
| Gentamicin (GM) | 0 (0 %) | 6 (5.4 %) | 0 (0 %) | ||
| Ceftazidime (CAZ) | 2 (1.8 %) | 14 (12.7 %) | 10 (9.1 %) |
|
|
| Cefepime (FEP) | 13 (11.8 %) | 15 (13.6 %) | 9 (8.2 %) | 1.705 | 0.426 |
| Cefazolin (CZ) | 18 (16.4 %) | 14 (12.7 %) | 15 (13.6 %) | 0.645 | 0.724 |
| Ciprofioxacin (CIP) | 22 (20 %) | 21 (19.1 %) | 9 (8.2 %) |
|
|
| Cefotaxime (CTX) | 14 (12.7 %) | 18 (16.4 %) | 14 (12.7 %) | 0.808 | 0.668 |
| Amoxicillin + Clav. Ac. (AMC) | 35 (31.8 %) | 28 (25.4 %) | 15 (13.6 %) |
|
|
| Tetracycline (TE) | 55 (50 %) | 52 (47.3 %) | 50 (45.4 %) | 0.462 | 0.794 |
NOTE: Bold numbers indicate statistical significance (P value < 0.05).